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Abstract
Background
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown aetiology and character-
ized by continuing hepatocellular inflammation and necrosis. Autoantibodies represent
accessible markers to measure the adaptive immune responses in the clinical investigation.
Protein microarrays have become an important tool to discriminate the disease state from
control groups, even though there is no agreed-upon standard to analyze the results.
Results
In the present study 15 sera of patients with AIH and 78 healthy donors (HD) have been
tested against 1626 proteins by an in house-developed array. Using a Partial Least Squares
Discriminant Analysis (PLS-DA) the resulting data interpretation led to the identification of
both new and previously identified proteins. Two new proteins AHPA9419 and Chondroad-
herin precursor (UNQ9419 and CHAD, respectively), and previously identified candidates
as well, have been confirmed in a validation phase by DELFIA assay using a new cohort of
AIH patients. A receiver operating characteristic analysis was used for the evaluation of bio-
marker candidates. The sensitivity of each autoantigen in AIH ranged from 65 to 88%; more-
over, when the combination of the two new autoantigens was analyzed, the sensitivity
increased to 95%.
Conclusions
Our findings demonstrate that the detection of autoantibodies against the two autoantigens
could improve the performance in discriminating AIH patients from control classes and in
combination with previously identified autoantigens and they could be used in diagnostic/
prognostic markers.
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Introduction
Autoimmune hepatitis is a complex disease and the diagnosis requires the exclusion of other
conditions and the presence of characteristic features such as specific autoantibodies. Presently,
these autoantibodies have relatively low sensitivity and specificity and are identified via immu-
nostaining of cells or tissues. Indeed, there are problems such as standardization and interpre-
tation of the immunostaining patterns [1]. To overcome these methodological problems, the
International Autoimmune Hepatitis Group established an international committee to define
guidelines, develop procedures and reference standards for more reliable testing [2, 3]. More-
over, serological overlap is frequently observed between AIH and other non-autoimmune liver
diseases such as chronic viral hepatitis [4]. Therefore, new and highly specific markers repre-
sent an unmet medical need for a more accurate diagnosis and classification of AIH. Autoanti-
gens identification represents a great contribution in early diagnosis and prognosis in
autoimmune diseases. The use of human protein microarrays has become one of the most
invaluable tool in the field of large-scale and high-throughput biology [5], and their use in
basic research, diagnostics and drug discovery has emerged as a great promise of medicine [6].
An interesting application of this technology is the identification of a serodiagnostic antigens
ensemble whose expression profiles can effectively unveil discriminating patterns providing
the classification of healthy and disease samples [7–9].
However, to date, the data analysis of protein microarrays to extrapolate biologically inter-
pretable results suffers from many issues that are still subject to debate and there is a compel-
ling necessity for bioinformatics strategies in which the identification of novel disease
biomarkers is performed automatically [10]. In particular, in protein microarrays, the achieve-
ment of biomarkers discovery depends on powerful antigen selection methods that can deal
with a low sample size and a high number of features [11].
Literature provides a wide spectrum of data mining methods to overcome the problem of
the curse of dimensionality [12, 13]; among them, several supervised techniques (i.e. Support
Vector Machine, Random Forest, Bayesian classification) represent helpful tools for classifica-
tion and biomarker discovery in clinical proteomics [14]. Here, we propose the application of
multivariate data analysis, such as partial least squares discriminant analysis (PLS-DA), to per-
form biomarker selection on human protein microarrays. The PLS-DA [15, 16] model has the
advantage of overcoming the so-called high dimensionality small sample problem [17] and it
takes into account the noise in the system and multicollinearity [18]. As a result of these prop-
erties, in recent years, feature-ranking methods are being successfully applied in the field of
gene expression analysis [19–22] but much less in the area of proteomics [23–30]. Here, using
human protein microarray containing 1626 proteins selected throughout the human genome
as described in our previous work [31] in combination with a bioinformatic approach based on
the partial least squares discriminant analysis (PLS-DA), we investigate whether we can 1) per-
form a fast and more accurate selection for novel biomarkers and 2) confirm autoantibody
responses of previously described biomarkers. For this purpose, a set of 263 serum samples
were selected from 55 patients with autoimmune liver diseases, 95 patients with viral hepatitis,
including 72 and 23 affected from hepatitis C virus and hepatitis B virus, respectively and 78
healthy donors (HD).
Two new AIH-specific autoantigens were identified, AHPA9419 and Chondroadherin pre-
cursor (UNQ9419 and CHAD, respectively) in addition to previously identified proteins. The
two novel autoantigens were validated using a different sera cohort and receiver operating
characteristic analysis showed a sensitivity ranging from of 65 to 87.5% and a specificity from
77.7% to 81.5%, respectively, for all control classes. These values are in line with the sensitivity
of other selected autoantigens reported in literature [25, 32].
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Herein, by combination of protein array and bioinformatics approach, two highly immuno-
reactive autoantigens, UNQ9419 and CHAD, with an AUC value greater than 0.70, were iden-
tified as specifically recognized by AIH patients. Interestingly, when the autoantigens were
combined with the purpose to create a clinically valuable panel, the AUC showed a value of
0.915, while the sensitivity and specificity were 95.0% and 76.2%, respectively. These results
indicate that the new autoantigens can be applied in clinical diagnostic and, together with the
known biomarkers, can be used in the AIH diagnosis to improve sensitivity and accuracy.
Materials and Methods
Ethics statement
The use of biological material (such as serum) from healthy donors for research purposes and
patients studies were approved by the Ethics Committee of IRCCS Ca’ Granda Policlinico
Ospedale Maggiore in Milan, Italy and Sant’Orsola University Hospital, Bologna, Italy, respec-
tively. Written informed consent regarding study participation was obtained from all involved
adults or from the next of kin. Children were not be involved in the study. The study was
approved by the Fondazione INGM Institutional Review Board (IRB).
Serum Samples
Human sera samples were obtained from 263 individuals in two different hospitals: Sant'Or-
sola-Malpighi University Hospital, Bologna, Italy and IRCCS Ca' Granda Ospedale Maggiore
Policlinico, Milan, Italy: 55 AIH, 72 HCV, 23 HBV and 113 healthy sobjects. The Table 1
reported clinical characterization of sera used for this study. AIH patients information from
both discovery and validation studies were clinically diagnosed according the scoring system
by the International Autoimmune Hepatitis Group and summarized in S1 Table (Supplemen-
tary Information section). Moreover, the level of IgG of the patients with AIH was higher than
upper limit of normal with a median value of 1,1 (0.75–1.76), and a score of the 77%, and 17%
(definite and probable respectively). All sample sera of patients with AIH were collected prior
to treatment and were stored frozen in aliquots at -80°C. Each aliquot has been thawed no
more than twice before use.
Fabrication of the Protein Microarray and its probing with Human sera
The human protein microarray used in this study was composed of 1626 polyptides and was
generated in INGM laboratory as previously described [31]. Briefly, after expression in E. coli
as His-tagged fusions and purified from the bacterial insoluble fraction (0.5 mg/ml in 6M
Urea), all human recombinant proteins were arrayed in a 384-well format and printed on
nitrocellulose-coated slides (FAST slides, GE-Healthcare) in quadruplicate with the Microgrid
II spotter (Biorobotics). A quality control of the spotting procedure was performed on 10% of
randomly chosen slides. The percentage of proteins successfully spotted on the slides was
assessed by hybridizing the microarrays with an α-His mAb, followed by an Alexa-647 conju-
gated α-Human IgG secondary antibody and estimating the number of spots with a mean fluo-
rescence intensity (MFI) value significantly above background. The spotted microarrays were
allowed to remain at room temperature for 1 h before storage at 4°C until use.
The probing procedure was identical for each microarray and conducted by TECAN
Hybridization Station (HS 4800™ Pro; TECAN, Salzburg, Austria). The slides were blocked
with BlockIt™Microarray Blocking Buffer (ArrayIt Corporation), than diluted sera were incu-
bated for 1 h at room temperature. Slides were then washed 3 times in PBST and probed for 1
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h at room temperature with Alexa-647-conjugated anti-human IgG (Invitrogen). After wash-
ing steps at 25°C, the slides were finally dried at 30°C under nitrogen for 2 min.
Scanning and image analysis
Protein microarray slides were scanned with a ScanArray Gx PLUS (PerkinElmer, Bridgeport
Avenue Shelton, USA) and analyzed using ImaGene 8.0 software (Biodiscovery Inc, CA, USA).
The fluorescence intensity of each spot was measured. To quantify signals we calculated the sig-
nal intensity for each protein spot, which was defined as the foreground mean intensity divided
by its local background mean intensity. When the signal was<0 the protein spot was assigned
the signal average of it for each group. We performed a within-array normalization for each
slide on the basis of the signal distribution of all points of the human IgG curve using in-house
developed software as previously described [33]. On the basis of these results, a normalized
MFI value of 4.000 (value corresponding to the normalized MFI value of negative controls—
BSA, HSA, Hu-GST- plus 2 standard deviations) was chosen as the lowest signal threshold for
scoring a protein as positively recognized by human sera [31]. Moreover, for each protein, a
Coefficient of Variation (CV%) was calculated on the four replicate spots for intra-assay repro-
ducibility. If the CV% value was not within the expected range, the antigen was not considered
for further analysis.
Protein microarray data analysis
Each protein microarray is encoded by a vector of sorted features and each of them represents
the normalized MFI of the pixels segmented as an autoantigen spot. Afterwards, the selected
descriptors were organized in a quantitative feature matrix where rows and columns corre-
spond to samples and autoantigens. To overcome the imbalance dataset issue the majority
class was used through sampling several subsets independently the class itself, use these subsets
to train classifiers separately and combine the trained classifiers into a final output (panel auto-
antigens). The female to male ratio of 3:1 was satisfied in the sampling selection of the majority
class. 50, R, randomly partitioned datasets were generated to this aim while stability of protein
profiles was assessed with Tanimoto index [34]. After computing the similarity index for each
pair of feature preferences, the final stability was defined as the averaged over all pair wise simi-
larity comparison between the fifty different protein sets (see Supporting Information).
Robustness assessment of selection techniques
To perform the stability analysis two feature selection techniques, as well as Recursive Support
Vector Machine (R-SVM) [35] and Partial Least Squares Discriminant Analysis (PLS-DA) [18,
Table 1. Serum samples used in this study.
Phase Group (Abbreviation) Subtype (n) n Sourcea Age: Mean± SD Sex (n)
Discovery Healthy Donors (HD) __ 78 1, 2 44 ±10 F(20) M(58)
Autoimmune Hepatitis (AIH) Type 1 (15) Type 2 (0) 15 2 50±21 F(13) M(2)
Validation Healthy Donors (HD) __ 35 1, 2 48 ±8 F(31) M(4)
Autoimmune Hepatitis (AIH) Type 1 (33) Type 2 (7) 40 2 53±16 F(34) M(6)
Viral hepatitis (VH) ^HCV (72) $HBV (23) 95 2 52±12 F(36) M(59)
aOrigin of samples: (1) IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Milan, Italy, (2) Sant’Orsola University Hospital, Bologna.
^Patients affected from Hepatitis C Virus and
$Hepatitis B Virus
doi:10.1371/journal.pone.0137927.t001
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36] were considered as representative of supervised feature selection methods. To assess the
robustness of feature selection techniques, each feature selection algorithms was run on each
generated R = 50 subsets, and the stability estimates were calculated within each datasets by 10
fold cross-validation results and the overall stability was averaged on all pair wise comparisons
(see Supporting Information). The pseudo-code of the stability analysis is reported in S2 Table.
PLS-DA, model validation and statistical analysis
PLS-DA was used for modelling the difference between AIH patients and HD controls [15, 16].
The model allows us to identify which descriptors explain most of the differences in the two
groups by means of the variable influence in projection (VIP). The VIP is a weighted sum of
squares of the PLS loading weights taking into account the amount of explained Y-variation in
each dimension. The rule “greater than one” was used for detecting the descriptors with the
greatest importance in the projection [18]. Validation of the PLS-DA model was checked using
cross-validation (CV) and response permutation testing [14]. A CV procedure allowed us to
randomly generate the necessary of training/test partitions from the original dataset. The dif-
ferences between actual and predicted responses (calculated as reported in [36]) were calcu-
lated from all the parallel models to form PRESS (predictive residual sum of squares); this was
a measure of goodness of prediction and generally it is re-expressed as Q2 (the cross-validated
R2) which is 1-PRESS/SS where SS is the sum of squares of the response, corrected for the
mean [18, 19]. One limitation of CV is that it provides over-optimistic results, so in order to
give a measure of the statistical significance of the estimated power, Q2Y, (diagnostic statistic)
and to test the model for over fitting due to chance correlation a permutation test was intro-
duced. In this test only the labels of Y-block were randomly reordered while the X-block (anti-
gen profiles) was intact. By repeating this procedure N times, a model is fitted to the new Y-
data and new estimates of R2Y and Q2Y values were calculated [18, 36]. In this way, a reference
distributions of R2Y and Q2Y are obtained, useful for appraising the statistical significance of
such parameters; if “real” values are found outside such distributions this is a sign of high valid-
ity of model [18]. All computational analyses have been run within the R statistical language
[37]. The plspm package (http://cran.r-project.org/web/packages/plspm/index.html) provides
R functions for PLS-DA algorithm. Potential biomarkers were selected based on VIP> 1, the
recognition frequency by less than 25% of the HD sera and more than 50% of AIH sera and the
relative frequency of autoantigens over the all generated datasets of 100%. A summary of the
proposed bioinformatic approach for proteomic biomarker discovery, described above, is sum-
marized in Fig 1.
Dissociation-enhanced Lanthanide Fluoroscence ImmunoAssay
(DELFIA
1
) and data analysis
For the experimental verification of the antigens selected, DELFIA
1
assay, a time-resolved fluo-
rescence method, was used as described previously [31]. In brief, 20 μg/ml purified recombi-
nant proteins (in 6M Urea) were coated in a 384-well format plates in duplicate with the
Fredom-Evo Liquid Handling (Tecan). The plates were blocked with a blocking reagent (Perki-
nElmer) than diluted sera was incubated for 1 hour at 37°C. The plates were then washed 5
times with washing buffer (PerkinElmer) and probed for 30 min at room temperature in the
dark with Europium-labeled α-human IgG serum (1:500 in diluting buffer, PerkinElmer).
After washing, using Hydrospeed™ (TECAN), plates were left at room temperature for 10 min
and finally read by an Infinite F200 PRO instrument (Tecan). Fluorescence intensity values
higher than the mean of HD plus 1 SEM were considered as positive.
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DELFIA
1
results were analyzed using the two-tailed X2 test, the Student’s t test, the Fisher’s
exact tests, or the analysis of variance test using either TIGRMultiexperiment Viewer and
GraphPad software.
The Epicalc package was used to obtain the Receiver Operating Characteristic (ROC) curves
of the models and the area under the curve (AUC) values.
STRING software (http://string-db.org) [38] was used to analyze the biological network of
UNQ9419 and CHAD.
Immunoblot Analysis
Five-hundred nanograms of AHPA9419 (UNQ9419) (secreted full length domain) was
expressed by E. coli with the His10 tag, such as 500 ng of Chondroadherin (CHAD) (secreted
domain) were resolved by 12% SDS-PAGE. The separated proteins were electrotransferred
onto nitrocellulose membranes (Biorad) according to the manufacturer’s instructions. After
blocking nonspecific binding sites with 5% nonfat milk powder diluted in PBS plus 0.1%
Tween 20 (TPBS). The membranes were incubated with anti-His antibody (GE Healthcare)
Fig 1. Workflow for signature selection profiles in protein microarrays. Protein microarray data were collected after scan image analysis and
subsequently pre-processed and normalized. A submodel design included a 50 random data set generated to make balanced the comparison. Than PLS-DA
was applied to visualize the separation between the two serum classes (AIH and HD) and to compute the discriminatory ability of each antigen to the
separation based on the variable importance in the projection (VIP). To give a measure of the statistical significance of the diagnostic statistics a statistical
model validation step was performed. In order to identify list of best candidates, a multi-criteria step based on recognition and relative frequency of
autoantigens was applied.
doi:10.1371/journal.pone.0137927.g001
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and secondary HRP-conjugated anti-mouse IgG (GE-Healthcare) were used to detect His-
tagged recombinant proteins. The recombinant CHAD and UNQ9419 proteins were detected
in the pooled serum from 6 cases of AIH and 6 control individuals (1:150), respectively O.N. at
4°C. After washes three times in TPBS, the secondary HRP-conjugated antibody (anti-mouse
IgG; GE-Healthcare) was diluted 1:1000 in TPBS and incubated for 1 h at room temperature.
Bound antibodies were detected by means of enhanced chemiluminescence (Super Signal West
Pico Chemiluminescence Substrate) (Thermo Scientific) and detected with LAS-3000 (Fujifilm,
Wayne, NJ).
Results
Quality check and pre-processing of protein microarray
To identify autoreactivity in patients with AIH, we used human protein microarrays carrying
1626 proteins, as previously reported [31]. The final protein microarray design consisted of 24
grids each of 304 spots, for a total of 7296 spots (Fig 2A).
The quality and quantity of the immobilized proteins on the microarray were determined
by probing with an anti-His mAb and 89% of the proteins produced signals that were signifi-
cantly above the background (Fig 2B). To identify potential AIH-associated autoantigens, we
used ImaGene 8.0 to acquire the resultant signal intensities of all protein spots in each assay
and an in-house developed software in order to select the positive spotted human proteins
within each microarray prior normalization (see details in “Materials and Methods”). The
results showed a high correlation among spot intensities of two different slides of the same
batch indicating a high reproducibility of the signals derived from the spotted proteins (Fig
2C).
Multivariate analysis and statistical model validation
In order to identify an AIH-associated signature profiles, we first evaluated the distribution of
the Mean Fluorescence Intensity (MFI) generated from sera of AIH patients to HD subjects.
AIH patients showed higher reactivity toward autoantigens than healthy donors (S1 Fig).
Then to further determine the overall feasibility of the bioinformatic strategy (see Fig 1), we
carried out the analysis in two phases.
In the first phase, we conducted a data preprocessing and submodels design in order to
overcome the imbalance problem of our samples and many (training) dataset were generated
to get balanced ones fulfilling the female prevalence requirement (see Supporting Information).
Moreover, since features extracted from different datasets might contain information of differ-
ent aspects, we conducted a stability analysis comparing the ability of two rankers to select sta-
ble protein lists across different datasets, such as PLS-DA and R-SVM. The analysis revealed
that PLS-DA outperforms R-SVM because it generated in average more similar protein lists.
Specifically, the average similarity over all pair wise comparison is 69% for PLS-DA and 31%
for R-SVM as showed in Fig 3.
In the second phase, the PLS-DA was performed on all samples. However, in order to screen
for outliers and to survey possible groupings [39] PCA was applied to the 50 balanced data sets.
As shown in Fig 4A, the score plot of the PCA model, for one possible dataset (nAIH = 15,
ñHD = 24), showed that AIH subjects were well separated from healthy controls with the
exception of one outlying HD sample. Indeed, the exclusion of this sample provided in average
more similar protein lists (S2 Fig); therefore, all variables related to this sample were removed
from further analyses due to this atypical behaviour (see Supporting Information).
An overview of the analysis of one PLS-DA model is presented in Fig 4B and 4C; according
to cross-validation three latent variables were sufficient to model the correlations within the
PLS-DA and Protein Arrays to Identify Biomarkers
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dataset with R2Y and Q2Y of 74.28% and 62.19%, respectively (Fig 4B) and reported in S4
Table. The first three components depict a clear separation between the two groups according
to their clinical conditions (Fig 4C). In particular, Fig 4D shows the Q2Y value for the original
model in red and the reference distribution of Q2Y based on permuted data in blue for one of
the considered dataset. It should be noted that the positive results of the model validation anal-
ysis give statistical relevance to the autoantigen changes suggesting that the non-expression
related variations induced by experimental artefacts such as sample handling, are adequately
compensated.
Fig 2. Human Protein Microarray: Quality check. (A) The protein microarray was probed with an anti-His mAb followed by a secondary anti-mouse
antibody Alexa-647-labeled. Recombinant human proteins were purified and printed in quadruplicate on nitrocellulose slides. (B) Number of proteins
detected with the anti-His mAb. About 90% of proteins were spotted with success on the slides (i.e about 90% of the proteins produced signals that were
significantly above the background signal). Histograms: Proteins were considered “Present” when at least two out of the four replicates gave a signal above
the background, otherwise they were considered “Absent”. (C) Correlation among spot intensities of two different slides (Slide 1 Vs Slide 45) of the same
batch. The scatter plot indicates a positive correlation. The correlation coefficient is 0.9, indicating a high reproducibility of the signals derived from the
proteins spotted.
doi:10.1371/journal.pone.0137927.g002
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Determination and evaluation of the biomarker candidates
Amulticriteria approach was used in order to define a targeted protein panel related to disease
condition (Fig 5). First, the variable importance in the projection (VIP) values of the biomarker
candidates was checked. Variables with VIP scores>1 were considered to have significant
influence on the explanation of the separation. Second, self proteins were regarded as potential
autoantigens if they were recognized by less than 25% of the HD sera and more than 50% of
AIH sera. Seventy variable passed the above criteria. Third, autoantigens with a relative fre-
quency (obtained from all generated datasets) less than 100% were excluded.
In this way, a list of 31 autoantigens was identified as discriminating between AIH subjects
and healthy controls (Table 2). Interestingly, the strategy outlined gave promising and reliable
results, indeed we confirmed that 87% (27 proteins) of these autoantigens were in common
with those reported in our previous work [31] and 4 (13%) were selected as new autoantigens.
These results confirmed that our approach is reliable. In order to confirm these 4 autoantigens,
further validation in a different and larger population was used to assess the biological
variation.
Validation of novel AIH-associated autoantigens
To validate the new four additional autoantigens of the 31 candidates selected by PLS-DA, we
determined their respective sensitivities and specificities for AIH with DELFIA
1
screening
Fig 3. Evaluation of feature stability.Robustness of the R-SVM and PLS-DA rankers across the different 50 datasets is plotted as heat maps. Columns
and rows represent the independent 50 subsets and each square indicates the Tanimoto index between two subsets. The colour code of the heat map
ranges from blue to red where a blue colour reflects a low similarity index suggesting few proteins in common between the subsets while a red colour denotes
an high similarity index. For each considered selection method a similarity heat map is obtained. (A), The average similarity over all pair wise comparison is
69% for PLS-DA; (B), and 31% for R-SVM; thus PLS-DA outperforms the R-SVM.
doi:10.1371/journal.pone.0137927.g003
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using a larger and an independent sample set of sera, The sera used included 40 AIH and 35
healthy controls. Two out of four proteins were statistically significant, with a sensitivity more
than 40%, (UNQ9419 45% and CHAD 53%), and showed a specificity of the 100% and 89%
respectively, in terms of recognition frequency. Moreover, because the AIH is a liver-specific
autoimmune disease, we determined their specificity using sera sample with liver disease from
Fig 4. Overview of the PLS-DA analysis for the comparison between AIH and HD group. The normalized Mean Fluorescence Intensity (MFI) from
microarray data was analyzed using PCA and PLS-DAmodels. (A) PCA shows that AIH (red circle) and HD (green triangle) have distinctive profiles with little
overlap between the two groups of samples; the exception was the sample HD0088 (blue arrow) so this sample was omitted from the subsequently
explorative analysis. (B) Plot of R2Y (explained variation) and Q2Y (predicted variation) shows how the considered parameters change as a function of
increasing model complexity. Three components were calculated through cross-validation, R2Y and Q2Y were 74.28% and 62.18% and resulted significant in
order to explain the relationship between the descriptor matrix and the class response. (C) PLS-DA 3D score plot reveals that each sample is found close to
the samples belonging to the same subgroup. Samples are coloured according to the disease status (AIH- red circle, HD green triangle—the axes of the plot
indicate PLS-DA component 1–3). (D) Density plot of the Q2Y values in the analysis of 1000 permutation tests, solid red line shows the real Q2Y value. Such
reference distribution can be seen as sign of the degrees of overfit and overprediction of the model. The permutation test showed that the real PLS-DAmodel
was not over-fitted and not over-predicted.
doi:10.1371/journal.pone.0137927.g004
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viral hepatitis. Ninety-five patients with chronic viral hepatitis (72 patients affected from Hepa-
titis C Virus, HCV and 23 from Hepatitis B Virus, HBV) were compared with the results of
AIH sera as reported in Fig 6A and 6B. These results showed a high correlation also in terms of
signal fluorescence intensities (see Fig 6C). Table 3 shows the sero-reactivity of the validation
sample sera and reveals that the combination of the two statistical significant hits enhances
sensitivity to 65%, but the specificity was unsatisfactory with a decreasing in the controls
group. In addition, our best candidate IL4-R was included in the analysis as control and
showed sensitivity and sensibility value higher than 60% in AIH patient sera, similar to the
published results (Table 3).
We next assessed the discrimination power of combination of the new autoantigens by vari-
able ranking criterion AUC (area under the curve) or area under the “receiver operating char-
acteristic” (ROC) curve which combines the sensitivity and specificity of a given marker for
Fig 5. Selection strategy of serum autoantigens. The Venn diagram shows the autoantigen selection obtained according to (i) VIP scores >1.0 and (ii) a
delta difference recognition frequency of 25%. 70 autoantigens overlap between the two filter criteria. Then, final selection of autoantigens was based on
relative frequency of autoantigens from all generated datasets. There were 31 variables that were present in all datasets.
doi:10.1371/journal.pone.0137927.g005
PLS-DA and Protein Arrays to Identify Biomarkers
PLOS ONE | DOI:10.1371/journal.pone.0137927 September 16, 2015 11 / 20
disease diagnosis which ranges from 0.5 (no discriminating power) to 1.0 (complete separa-
tion) [40]. Similar approach has been reported in a previous work, where Zingaretti et al.
showed that the power of the combination of four antigens in discriminating AIH from healthy
individuals was better than a single autoantigen [25]. Therefore, ROC analysis of two novel
potential biomarkers was carried out to validate the newly selected autoantigens and examine
their contribution to the prediction of AIH (Fig 6D). All samples without autoimmune hepati-
tis, including patients affected by HCV, HBV, and healthy individuals, were used as unique
control class (here called no AIH).
The results of ROC analysis and the variables are ranked according to their AUC, either sin-
gle and in combination. UNQ9419 had the highest AUC of 0.899. At the best cut-off point (Fig
Table 2. Overview of autoantigens identified as potential signature profile of AIH. List of autoantigens involved in the discrimination between disease
and healthy group. Using a VIP score>1 and a recognition frequency by less than 25% in HD and more than 50% in AIH a set of possible autoantigens was
extracted. Features from all generated models were identified and compiled into a single list.
Description Protein ID VIP^ HD% AIH%
Interleukin 4 receptor IL4R 1.57 0 67
Lysozyme g-like protein 1 Precursor LYG1 1.38 4 73
Uncharacterized protein C19orf47 C19orf47 2.04 4 80
Solute carrier family 22 member 23 SLC22A23 1.22 0 60
Putative uncharacterized protein UNQ5830 1.94 0 80
Putative uncharacterized protein DKFZp667F0711 AL137145.1 1.91 1 87
Hypothetical protein LOC648852 LOC648852 1.32 0 60
Putative uncharacterized protein LOC646100 1.68 0 73
Uncharacterized protein C17orf99 Precursor C17orf99 1.46 0 73
Uncharacterized protein C17orf99 Precursor C17orf99 1.6 0 67
UPF0631 protein HSD24 AC130289.1 1.23 0 60
Transmembrane 95 Precursor TMEM95 1.12 0 60
Cys-rich secr. prot. LCCL domain- containing 2 CRISPLD2 1.21 1 60
Ankyrin repeat domain- protein 43 Precursor ANKRD43 1.27 0 60
RPE-spondin Precursor C8orf84 1.42 0 67
Carboxypeptidase-like protein X2 Precursor CPXM2 1.83 0 80
DnaJ homolog subfamily C member 30 DNAJC30 1.44 4 73
Chondroadherin-like Precursor CHADL 1.14 4 73
Protein APCDD1-like Precursor APCDD1L 1.49 0 73
Putative uncharacterized protein AC016586 1.45 0 60
VGSA5840 AC060225 1.3 0 60
AHPA9419 UNQ9419 1.36 0 53
Calcium homeostasis modulator protein 3 CALHM3 1.25 0 80
T cell receptor beta variable 7 A0A598 1.24 0 53
Putative uncharacterized protein AC007245 1.33 0 67
Thymic stromal cotransporter homolog SLC46A2 1.21 0 67
Inhibin beta E chain Precursor INHBE 1.51 0 60
WFDC10B Precursor WFDC10B 1.1 0 60
R-spondin-3 Precursor RSPO3 1.08 0 53
Membrane progestin receptor alpha PAQR7 1.5 0 80
Chondroadherin Precursor CHAD 1.65 1 87
HD: healthy donors; AIH: Autoimmune hepatitis patients.
^Average over 50 dataset.
doi:10.1371/journal.pone.0137927.t002
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6D) 87.5% sensitivity and 77.7% specificity were obtained. Autoantigens were then combined
for the purpose of building a clinically valuable panel. The AUC showed a value of 0.915 while
the sensitivity and specificity were 95.0% and 76.2%, respectively (Fig 6D). In all, these results
indicated that the new autoantigens can be applied in clinical diagnostic and, together with the
known biomarkers, can be used in the AIH diagnosis to improve the sensitivity and accuracy.
Finally, the two novel autoantigens were also detected in the pooled serum from 6 AIH
patients rather than no-AIH individuals, which indicated the capability of human sera to rec-
ognize the specific bands of UNQ9419 and CHAD. SDS-PAGE and western blot analysis,
Fig 6. Evaluation of AIH-associated autoantigens. (A) The heatmap summarizes the recognition frequencies among different sample groups (AIH, HD
and the VH) for the new four autoantigens out of the 31 candidates selected with the proposed bioinformatic strategy after DELFIA screening. Colour intensity
denotes the degree of recognition frequency within the sample group. (B) Recognition frequency for two of the four autoantigens, that were statistical
significant. (C) Signals distribution detected for each of the new two proteins are displayed. Statistical differences in recognition frequency (ChiSquare test)
and in signal intensity (t test) are denoted as single (p<0,05), double (p<0,001) or triple stars (p <0,0001). (D), ROC curve of the biomarker candidates
exhibited AUCs of 0.899 (SE = 87.5% and SP = 77.7%), 0.782 (SE = 65.0% and SP = 81.5%) for UNQ9419 and CHAD, respectively. The arrows denote best
cut-off points. Combo curve represents the combination, UNQ9419+CHAD, which exhibited AUC of 0.915 (SE = 95.0% and SP = 76.2%).
doi:10.1371/journal.pone.0137927.g006
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detected by anti-His antibody, showed that the bands of purified recombinant UNQ9419 and
CHAD proteins appeared at 10.5 kDa and 18.2 kDa, respectively, which were similar to the
expected molecular weight (Fig 7).
In order to analyze potential roles of UNQ9419 and CHAD in inflammatory disease, the
intrinsic interactions with other proteins were analyzed using STRING software [38]. In the
protein interaction maps obtained for CHAD twenty-one interacting proteins were predicted,
including most interactions with several types of integrins, while for UNQ9419 a single interac-
tion detected with low score (see S3 Fig).
Discussion
We describe here the use of protein arrays in association with PLS-DA multivariate analysis in
order to obtain a series of autoantigens recognized by autoantibodies in the serum of autoim-
mune hepatitis patients, and suggest that they could be used either alone and/or in combina-
tion as diagnostic markers. To achieve this goal we screened autoantibodies repertoires in 15
individuals with AIH and 78 healthy donors using a in house-developed protein array [31].
Specifically, we took into consideration the importance of the data analysis and potential
hazards of interpretation. Indeed we wanted to improve the selection pipeline to highlight a
complete and exhaustive list of discriminating features, overcoming the small sample size prob-
lem and applying a more rapid and accurate strategy. Proteomics dataset are characterized by
few samples compared to the total number of variables and this undersampling can lead to
problems such as features selection whose discriminatory power is purely due to chance or
overfitting derived model which is specific for the selected dataset. The intrinsic characteristics
of multivariate techniques coupled with a statistical validation strategies, such as cross-valida-
tion and permutation tests, make them ideal for the analysis of the proteomics datasets over-
coming the many issues concerning the data analysis in this field. Differently from our
previous work [31], we decided to focus on multivariate approaches simply because they get to
capture feature redundancy and interaction neglected by univariate methods which evaluate
each feature in isolation from all other and without any direct relation to the classification
algorithm.
In order to provide a condensed signature profiles we also chose to apply a multi criteria
based on recognition frequency and relative frequency of autoantigens over all datasets. Of
note, this more representative panel, composed of 31 autoantigens, has a large number of dis-
criminating features (about 87%) in common with the autoantigens seen in our previous work
obtained by using a univariate data analysis [31]. The validity of these findings supports the
Table 3. Overview of sensitivity and specificity in a validation step.
Description Symbol Combo aSE % bSP % HD cSP % VH
Interleukin 4 receptor domain IL4R 63 97 96
AHPA9419 UNQ9419 • 45 100 98
Chondroadherin Precursor CHAD • 53 89 91
T cell receptor beta variable 7 TCR-B7 18 100 99
Combination UNQ9419+ CHAD 65 89 88
a Sensitivity is deﬁned as the true positive rate in %.
b Speciﬁcity is deﬁned as the true negative rate in Healthy Donor (HD)subject in %.
c Speciﬁcity is deﬁned as the true negative rate in Viral Hepatitis (VH)patients in %.
doi:10.1371/journal.pone.0137927.t003
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feasibility of using supervised machine learning methods in combination with protein
microarrays.
The reported results show that the outlined strategy is a valid support to proteomics studies.
Firstly, the approach proved to be highly reliable and reproducible, providing a fast discrimina-
tion tool; additionally, protein microarray data are processed in automatic and unbiased proce-
dure reducing errors; indeed it may highlight the presence of samples with divergent
proteomic pattern then excluding them.
Six proteins in the newly selected list were already validated and showed high sensitivity
(from 42% to 70% of positive AIH patients) and specificity (from 96% to 100% of negative
HDs), as previously reported [31]. Among validated proteins, IL4 receptor autoantigen was
Fig 7. AIH sera recognize UNQ9419 and CHAD. (A), SDS-PAGE (left panel) and western blot against anti-His antibody analysis (right panel) of the purified
UNQ9419 and CHAD recombinant proteins. (B), western blot analysis of the purified UNQ9419 and CHAD recombinant proteins against sera from AIH
patients (left panel) and no AIH subjects (right panel), respectively.
doi:10.1371/journal.pone.0137927.g007
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studied for the neutralization role in autoimmune hepatitis, demonstrating that IL4R autoanti-
bodies are functional in autoimmune hepatitis disease.
In this study we selected a list of proteins that included potential new biomarkers in autoim-
mune hepatitis and we validated four proteins that were not previously found to verify if they
could be valid biomarkers. It was not surprising that there was not a completely overlap
between the two selected list. Indeed, the two approaches are quite different: the traditional one
[31] is based on the MFI of a single autoantigens related through the different microarrays
whereas the described strategy, based on multivariate techniques, takes into account the feature
interdependencies in the feature selection process. Moreover, it should be noted that these
potential biomarkers differ from those discovered by other groups in previous studies [8, 9]
because our protein array is designed to target either membrane-associated or secreted pro-
teins, and great majority of which are poorly characterized and with unknown function [41].
Indeed, we were able to validated two new autoantigens for all control classes. ROC analysis
shows that the putative biomarkers achieve a sensitivity and specificity ranging from 65% to
87.5% and from 77.7% to 81.5%, respectively. When UNQ9419 and CHAD were analyzed in
combination the sensitivity and specificity were 95% and 76.2%, respectively.
One of the two new biomarker candidates is a protein with unknown function, annotated as
AHPA9419 (UNQ9419), the other is a protein known as chondroadherin precursor (CHAD)
(New UniProtKB accession number format in release 2014_06). CHAD is a short leucine rich-
repeat protein (SLRP), a family of proteoglycans that have key roles as potent effectors in cellu-
lar signaling pathways [42]. Recent research studies have shown that SLRPs regulate biological
functions in many tissues such as skin, tendon, kidney,liver, and heart [43, 44]. It has been also
reported the role of decorin (a SLRP member protein) in extracellular matrix of liver fibrosis as
inhibitor of TGF-β [45], the most powerful profibrotic cytokine, and studies suggest the pres-
ence of other SLPR members, such as CHAD, in attenuating TGF-β bioactivity [46–48]. In the
web-network analysis we found that CHAD include mostly interactions with integrins, trans-
membrane receptors involved in the attachment of the cell to the extracellular matrix (ECM)
and signal transduction from the ECM to the cell. It has been also shown that integrins medi-
ated activation of TGF- β pathway in inflammation process [49]. Moreover, knowledge of the
relationship between integrins and receptor tyrosine kinase has laid a foundation for new
approaches to cancer therapy [50].
In this perspective further understanding of the possible pathological role of CHAD protein
and presence of its autoantibodies in autoimmune hepatitis should pave the way of new thera-
pies. Then, additional efforts will be useful for the identification and characterization of
UNQ9419 protein.
Conclusions
Autoimmune hepatitis is a complex disease characterized by the presence of circulating auto-
antibodies, hypergammaglobulinemia, necroinflammatory changes on hepatic histology and a
dramatic response to immunosuppressive therapy [51]. A “biomarkers profile” containing a
combination of benchmarks in clinical use and our best candidates [31] might help to better
discriminate specific pathologies that share common features with autoimmune liver diseases
and could be more informative for elucidating the pathology and clinical status [52]. The use of
information from serum patterns of each patient will lead to the development of customized
therapy.
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Supporting Information
S1 Fig. Comparative profiling between analyzed classes. Representative Mean Fluorescence
Intensity (MFI) distribution of healthy donor subjects (HD, top panel) compared with Autoim-
mune Hepatitis patients (AIH, bottom panel).
(PDF)
S2 Fig. Stability comparison with and w/o HD0088. (A) We conducted a similarity analysis,
based on PLS-DA with and (B) without HD0088 sample to strengthen the results obtained by
PCA. Indeed, the exclusion of this sample provides in average more similar protein lists relative
to the analysis with the cited sample, therefore, all variables related to this sample were
removed from further analyses due to this ambiguous behaviour.
(PDF)
S3 Fig. Protein interaction network. Proteins involved in UNQ9419 and CHAD functions
were analyzed using STRING software. Different line colours represent the types of evidence
for the association predicted by different methods., shows a signiﬁcant protein interaction
from the reports of literatures; shows a signiﬁcant protein interaction groups gathered from
databases; shows protein interaction groups extracted from scientiﬁc literatures. (A) This
network received a low score. Predicted functional partner was only one protein: KIAA1524,
an oncoprotein that inhibits PP2A and stabilizes MYC in human malignancies. Promotes
anchorage-independent cell growth and tumour formation. (B) This network received a score
of more than 0,8. The predicted function includes integrins, transmembrane receptors that are
the bridges for cell-cell and cell-extracellular matrix (ECM) interactions. 10/21 interacting pro-
teins for CHAD are depicted as: ITGA2, integrin, alpha 2; ITGA4, integrin, alpha 4; ITGA5,
integrin, alpha 5; ITGA6, integrin, alpha 6; ITGB1, integrin, beta 1; ITGB5, integrin, beta 5;
ITGB6, integrin, beta 6; ITGA8, integrin, alpha 8; ITGA10, integrin, alpha 10; ITGA11, integ-
rin, alpha 11.
(PDF)
S1 Table. Antibody response and clinical characteristics of AIH patients.
(PDF)
S2 Table. Pseudo-code of the robustness of feature selection algorithms.
(PDF)
S3 Table. Model performance of PLS-DA models for the AIH vs HD comparison. Summary
statistics of the PLS-DA models for the fifty dataset. A cross-validation strategy was employed
to give an estimate of the significance of a latent variables; an appropriate number of compo-
nents is given where model have an optimal balance between fit (R2Y, explained variation) and
predictive ability (Q2Y, predicted variation). Most models are well modelled after three PLS
components, but there are some exceptions.
(PDF)
S4 Table. Summary statistics of one PLS-DA models for the AIH vs HD comparison. Over-
all R2Y and Q2Y statistics change as a function of increasing model complexity (for one of the
fifty generated submodels). Here the cross-validation procedure suggests that three compo-
nents are appropriate to explore the correlations within dataset. The three components explain
74.28% (R2Y = 0.74) and predict 62.19% (Q2Y = 0.62) of the variation in the response variable.
(PDF)
S1 Text. Protein Microarray data analysis.
(PDF)
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